|Test Method Number:||TM2011-09 (EU)|
|Short Name of TM:||GARD|
|Submission received on:||October, 2011|
|Responsible Organisation:||EURL ECVAM - European Union|
|Stage of Submission:||Assessment Finalised|
|General Comments:||Project proposal does not meet the needs for addition to work programme of the OECD TG Programme (11/01/2016)|
GARD addresses the third key event of the skin sensitisation Adverse Outcome Pathway (activation of dendritic cells): step 5 (biochemical pathways related to skin sensitisation) and step 6 (immune recognition of chemical allergens and maturation of dendritic cells (DCs)).
MUTZ-3 human acute myelomonocytic leukemia cell line in its differentiated form, expresses a phenotype resembling the one of immature primary DC or Langerhans-like DCs and is therefore considered a relevant model for DCs.
The test method measures, with Affymetrix gene array technology, the mRNA expression levels of a panel of 200 genes called the...